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We describe the first case of Epstein-Barr virus (EBV)-associated thymic carcinoid tumor found by in situ
hybridization (ISH) on paraffin-embedded sections. ISH revealed that both tumor cells and infiltrated lym-
phocytes were EBV positive, while a few EBV-infected lymphocytes were detected in 2 of 11 thymuses and 1 of
11 thymomas.
CASE REPORT
A 72-year-old Japanese man with a 3-week history of back
pain initially presented with a right upper anterior mediastinal
mass discovered by chest roentgenography and computed to-
mography in Shimonoseki-saiseikai Hospital, Shimonoseki, Ja-
pan. There was no evidence of Cushing’s syndrome, definite
carcinoid syndrome, or myasthenia gravis in his medical his-
tory. Laboratory examinations showed all data to be in normal
ranges, except for elevated values of serum lactic dehydroge-
nase and alkaline phosphatase. A mass arising from the right
lobe of the thymus to the right side of the mediastinum was
observed when a thoracotomy via midline sternotomy was per-
formed. The tumor had invaded the right upper and middle
lobes of the lung, the phrenic nerve, and the mediastinal lymph
nodes. Even though the patient received appropriate postop-
erative chemotherapy, he suffered vertebral metastasis that
induced paralysis of the lower extremities, and he eventually
died of progression of the disease.
The surgically removed thymic tumor (8 by 4 by 4 cm) was
fixed in formalin, embedded in paraffin, and sectioned for
routine histological examination. A piece of the thymic tumor
was subjected to transmission electron microscopy. The tumor
was histologically composed of solid nests of polygonal cells in
a characteristic rosette formation. Mitosis was seen occasion-
ally, and focal to geographic necrosis was evident in the tumor
tissue. A considerable number of lymphocytes were distributed
among the tumor nests. Transmission electron microscopy re-
vealed that distinct electron-dense granules with a diameter of
15 to 40 nm surrounded by a halo were seen in the cytoplasm
of most tumor cells, indicating structures corresponding to
neurosecretory granules (Fig. 1). Grimelius staining revealed
that a considerable number of tumor cells had dark-brown
granules in their cytoplasm.
Immunohistochemical staining with 11 commercially avail-
able antibodies—EBNA2 (Dako Japan Co., Ltd., Kyoto, Ja-
pan), ZEBRA (Dako), virus capsid antigen (VCA) (Dako),
latent membrane protein (LMP) (Dako), CD45RO (UCHL1)
(Nichirei, Tokyo, Japan), CD20 (L26) (Dako), CD7 (Dako),
neuron-specific enolase (NSE) (Dako), chromogranin A
(Dako), Bcl-2 (Dako), and p53 (Oncogene Science, Cam-
bridge, Mass.)—was performed, demonstrating that the tumor
cells reacted with p53, NSE, and chromogranin A antibodies.
Thus, the tumor was determined to be a thymic carcinoid
tumor. The identities of Epstein-Barr virus (EBV)-related pro-
teins above follow. EBNA2 is necessary to provide the growth
stimulus for B cells in vitro and in classical posttransplant
lymphoproliferative disease. ZEBRA, the BZLF1-encoded
protein, is not expressed during latent infection; however, ac-
tivation of the immediate-early gene BZLF1 is required to
switch from latent to lytic infection in host cells (6). Antibody
against VCA produced in lytic infection is routinely used to
diagnose EBV infection by serological examination.
Next, to identify EBV-related genes and transcripts in the
tumor, in situ hybridization (ISH) with four alkaline phos-
phatase-labeled EBV gene-specific antisense oligoprobes, in-
cluding EBV-encoded small RNA 1 (EBER1), BamHI-W, la-
tent membrane protein 1 (LMP1), and gp350/220 (a
component of VCA) (Iatron Laboratories, Chiba, Japan), and
two digoxigenin-labeled EBV gene-specific riboprobes, BZLF1
and BHRF1, generated by in vitro transcription (Boehringer,
Mannheim, Germany) was performed as described previously
(17, 26, 27). ISH with four oligoprobes revealed that cells that
were almost neoplastic and contiguous lymphocytes were pos-
itive only for EBER1 (Fig. 2), indicating the presence of an
EBV-associated carcinoid tumor. EBV positivity on the section
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has been determined primarily by ISH with the specific probe
EBER1. There were abundant EBER1 transcripts (approxi-
mately 107 copies per cells), which exist as ribonucleoprotein
particles complexed with the cellular La antigen in EBV-in-
fected cells and EBV-associated tumors, except for oral hairy
leukoplakia in which no EBER1 was detected (12).
Furthermore, according to previously published methods
(26, 27), the nucleic extracts (DNA and RNA) obtained from
FIG. 1. Photomicrograph of the tumor showing that the tumor is composed of solid nests of polygonal cells with necrosis and lymphocyte
infiltration. These tumor cells have hyperchromatic and prominent nucleoli. The tissue sections were stained by hematoxylin-eosin-staining.
Arrowheads point to infiltrated lymphocytes. Magnification, 20. (Inset) Transmission electron micrograph showing that neurosecretory granules
are clearly seen in the cytoplasm of a tumor cell. Inset magnification, 20,000. Bar, 50 nm.
FIG. 2. ISH reveals that tumor cells and lymphocytes are positive for EBER1. Magnification, 20. (Inset) Cells show no signal against EBER1
sense oligoprobe utilized as a negative control. The arrowhead point to infiltrated lymphocytes. Magnification, 20.
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sectioned tissues were subjected to PCR for EBV genome,
reverse transcription-PCR for EBER1, and Southern blot hy-
bridization with appropriate primers and probes, demonstrat-
ing that EBV genomic DNA and EBER1 were presented.
Immunohistochemical examination showed that the EBV-in-
fected lymphocytes reacted with CD45RO (UCHL1) and CD7
antibodies, indicating that the lymphocytes were NK or T lym-
phocytes. These results are summarized in Table 1. Taken
together, EBV-infected tumor cells expressed p53 protein but
not LMP1 or Bcl-2, and the status of EBV detected in both
tumor cells and NK or T lymphocytes in tissue surrounding the
tumor was not replication phase, since neither VCA nor the
BZLF1 transcript, whose product mediates lytic replication of
EBV (6), was detected.
To determine the distribution of EBV-infected cells in the
thymus, ISH with EBER1 probe was performed on 20 consec-
utive sections each from 11 normal thymuses (7 males and 4
females; average age of 79 years) obtained from Shimonosek-
ishi-ishikai Hospital, and 11 thymomas without myasthenia
gravis obtained from both Shimonosekishi-ishikai and Shi-
monoseki-saiseikai Hospitals. Only a very small number of
lymphocytes infected with EBV were detected in two normal
thymuses and one thymoma.
EBV, a B-lymphotropic gammaherpesvirus, is associated
with a number of human malignancies, such as B-cell, T-cell,
and NK lymphomas, nasopharyngeal carcinoma, and gastric
carcinoma as well as disorders in the thymus (5, 19, 20, 21).
EBV in the thymus and various thymic tumors has not always
been detected in southern Chinese (21), European (2), and
Western subjects (16). ISH with EBER1 probe showed EBV in
malignant epithelial cells in one case of thymic lymphoepithe-
lioma-like carcinoma but not in thymic carcinoma, normal
thymus, thymoma, or thymic lymphoid hyperplasia (20). Stud-
ies of Taiwanese subjects by PCR and ISH with EBER1 probe
showed that lymphoepithelioma-like thymic carcinoma was
more often associated with the virus than other thymic tumors
(5), indicating that EBV-associated thymic diseases may be
linked to epidemiologic factors or genetic predisposition; oth-
erwise, the sensitivity of the methodology used may affect these
results. The occurrence of carcinoid tumor in the thymus is
rare and defined on the basis of mitotic activity and severity of
tumor invasion and has a better prognosis than tumors accom-
panied by necrosis or infiltrated lymphocytes, as in the case
presented here. However, the reason for such different prog-
noses has not been explained. The EBV-associated neoplasms
generally have relatively worse prognoses and more aggressive
behavior compared to non-EBV-associated neoplasms, de-
pending on the virus status, such as profiles of viral gene
expression which eventually affect signal transduction in the
infected cell (8, 13, 22).
In this case of EBV-associated thymic carcinoid, EBV was
detected in tumor cells and contiguous infiltrated lymphocytes,
and the EBV status and characteristics of both EBV-infected
cells are determined. The fact that EBV in most of the mor-
phologically malignant cells was in a nonreplicating stage was
interpreted to mean that the virus must have invaded the target
cells prior to neoplastic transformation and clonal prolifera-
tion; if EBV infection had been a late event, it is highly unlikely
that these tumor cells would have become infected.
The pathogenesis and interrelationships of neuroendocrine
carcinomas are not well understood. Mutation of the beta-
catenin gene (10), Int-2 allelic imbalance (9), and mitogen-
activated protein kinase activation (18) of carcinoid tumors
have been described. Studying the methylation profiles of car-
cinoid tumors revealed that methylation at MGMT (O6-meth-
yl-guanine methyltransferase), THBS1 (thrombospondin 1),
p14, and RAR (retinoic acid receptor  2) loci was more
frequent in carcinoid tumors, which reflect molecular patho-
genesis (4).
On the other hand, it is well-known that LMP1, which was
not detected in this study, induces activation of several signal-
ing pathway by NF-B-, JNK-, and STAT-mediated transcrip-
tion (8, 13, 22), leading to the onset of neoplasms at an early
stage. At earlier stages of carcinogenesis, LMP1 might be tran-
siently expressed immediately after an incident of EBV infec-
tion and transform primary neuroendocrine cells. EBV LMP1
is an immunodominant antigen, so disease caused by it, such as
infectious mononucleosis, can be cured spontaneously by cy-
totoxic T lymphocytes. In this case, EBV-infected cells might
escape from immunosurveillance in the host due to the ab-
sence of LMP1. Among the carcinoid tumors accompanied by
infiltrated lymphocytes, the EBV-associated one might exist, as
in this case.
An in vivo study utilizing transgenic mice in which adenovi-
rus genes (E1A or E1B) were chromosomally integrated doc-
umented that such viral genes caused the early onset of bowel
carcinoid tumors with high levels of N-myc and c-jun mRNA
(25). In our case, it is unclear whether EBV was integrated into
TABLE 1. Summary of immunohistochemical and ISH results
Stain, antibody, or targeted
DNA or transcript
Result or reaction of:
Tumor cell Lymphocyte
Grimelius stain  
Immunohistochemical staining
antibodies
UCHL1  
CD7  
L26  
EBNA2  
LMP1  
ZEBRA  
VCA  
p53  
Bcl-2  
NSE  
Chromogranin A  
ISH targets
EBV genomic DNAa  
Transcripts
EBER1  
LMP1  
gp350/220 (VCA)  
BHRF1  
BZLF1  
a Results shown were obtained with oligoprobe BamHI-W.
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the chromosome or colocalized in the chromosome as a plas-
mid form. However, we were not able to exclude the possibility
that viral gene expression of EBV stably exists in the nucleus,
comparable to adenovirus, interfering with the transcriptional
regulation of the promoter region of nuclear oncogene activa-
tion and with transformation and/or exerting CpG island meth-
ylation.
Furthermore, fluorescence ISH with locus-specific DNA
probes demonstrated a high incidence of deletion of the tumor
suppressor genes p53 and retinoblastoma (Rb), indicating that
structural genomic alterations are frequent in neuroendocrine
lung carcinomas and that their occurrence may be underesti-
mated by immunohistochemical studies alone (14). Some
EBV-infected cells possessed BHRF1 transcript, and the
BHRF1 sequence was homologous to the bcl-2 oncogene (24),
whose product (Bcl-2) is a major negative regulator of apopto-
sis.
In addition, p53 was immunohistochemically detected in
tumor cells, indicating that EBV effects abnormal cell pro-
liferation via evasion of apoptosis. Tumors expressing Bcl-2
generally correlate with a propensity for more aggressive
biological behavior and worse prognosis. The patient in this
case did not respond well to treatment, even though there
was a lack of Bcl-2 expression. However, BHRF1 transcript
was detected, suggesting that the putative viral protein from
BHRF1, instead of Bcl-2, may reflect such clinical features
with mutation in the p53 gene (7, 15). It should be noted
that the sensitivity of available methods on tissue sections is
limited. To clarify a causal relationship between EBV infec-
tion and carcinoid tumor might demand further improve-
ments in methodology on tissue sections such as in situ PCR
(17, 27).
The results from studies of ISH with EBER1 probe using 11
thymuses and 11 thymomas demonstrated that a few EBV-
positive lymphocytes in 2 normal thymuses and one thymoma
were detected, indicating that there are certainly EBV-infected
lymphocytes in the thymus. Evidence supporting the presence
of the EBV genome in NK or T lymphocytes has been reported
previously (1, 11, 23, 28). Regarding our case, we thus hypoth-
esize that the thymic carcinoid tumor may have arisen in a
peculiar microenvironment, such as proliferation of EBV-in-
fected NK or T lymphocytes or immature cells. The EBV
produced from such cells might more efficiently infect cells,
including neuroendocrine cells or primitive cell-like pluripo-
tential endodermal cells in the early phase of tumorigenicity
due to alteration of virus tropism (3).
In conclusion, in this report, we described the first case of
EBV-associated thymic carcinoid and investigated the EBV
status in this patient and examined the distribution of EBV-
infected cells in the thymuses and thymomas of other patients.
These results imply that EBV infection may have contributed
to the development of the tumor in this case. However, more
investigation with a larger number of clinical cases and molec-
ular-based analyses both in vitro and in vivo are needed to
elucidate the potential contribution of EBV to the pathogen-
esis of this very rare tumor type.
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